Zhao L, Cao YJ. Engineered T cell therapy for cancer in the clinic. Front Immunol. 2019;10:2250.
CAS PubMed PubMed Central Article Google Scholar
Weber EW, Maus MV, Mackall CL. The emerging landscape of immune cell therapies. Cell. 2020;181(1):46–62.
CAS PubMed PubMed Central Article Google Scholar
Ecsedi M, McAfee MS, Chapuis AG. The anticancer potential of T cell receptor-engineered T cells. Trends Cancer. 2021;7(1):48–56.
CAS PubMed Article Google Scholar
Zhao Q, Jiang Y, Xiang S, Kaboli PJ, Shen J, Zhao Y, et al. Engineered TCR-T cell immunotherapy in anticancer precision medicine: pros and cons. Front Immunol. 2021;12:658753.
CAS PubMed PubMed Central Article Google Scholar
Dai H, Wu Z, Jia H, Tong C, Guo Y, Ti D, et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol. 2020;13(1):30.
PubMed PubMed Central Article CAS Google Scholar
Huang R, Li X, He Y, Zhu W, Gao L, Liu Y, et al. Recent advances in CAR-T cell engineering. J Hematol Oncol. 2020;13(1):86.
PubMed PubMed Central Article CAS Google Scholar
Tian YG, Li YL, Shao YP, Zhang Y. Gene modification strategies for next-generation CAR T cells against solid cancers. J Hematol Oncol. 2020;13(1):54.
PubMed PubMed Central Article CAS Google Scholar
Zhang H, Zhao P, Huang H. Engineering better chimeric antigen receptor T cells. Exp Hematol Oncol. 2020;9(1):34.
CAS PubMed PubMed Central Article Google Scholar
Jiang Z, Sun H, Yu J, Tian W, Song Y. Targeting CD47 for cancer immunotherapy. J Hematol Oncol. 2021;14(1):180.
CAS PubMed PubMed Central Article Google Scholar
Shi JZ, Zhang ZJ, Cen H, Wu H, Zhang SK, Liu JX, et al. CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity. J Hematol Oncol. 2021;14(1):162.
CAS PubMed PubMed Central Article Google Scholar
Su CT, Ye JC. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond. J Hematol Oncol. 2021;14(1):115.
CAS PubMed PubMed Central Article Google Scholar
Zheng Y, Si J, Yuan T, Ding S, Tian C. Immune targeted therapy for diffuse large B cell lymphoma. Blood Science. 2021;3(4):136–48.
PubMed PubMed Central Article Google Scholar
Zhang YK, Li YQ. T cell receptor-engineered T cells for leukemia immunotherapy. Cancer Cell Int. 2019;19:2.
CAS PubMed PubMed Central Article Google Scholar
Liu HT, Pan CX, Song WR, Liu DL, Li ZH, Zheng L. Novel strategies for immuno-oncology breakthroughs with cell therapy. Biomark Res. 2021;9(1):62.
PubMed PubMed Central Article Google Scholar
Tan E, Gakhar N, Kirtane K. TCR gene-engineered cell therapy for solid tumors. Best Pract Res Clin Haematol. 2021;34(3):101285.
CAS PubMed Article Google Scholar
Tsimberidou AM, Van Morris K, Vo HH, Eck S, Lin YF, Rivas JM, et al. T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors. J Hematol Oncol. 2021;14(1):102.
CAS PubMed PubMed Central Article Google Scholar
Zhang J, Wang L. The emerging world of TCR-T cell trials against cancer: a systematic review. Technol Cancer Res Treat. 2019;18:1533033819831068.
CAS PubMed PubMed Central Google Scholar
Shah K, Al-Haidari A, Sun J, Kazi JU. T cell receptor (TCR) signaling in health and disease. Signal Transduct Target Ther. 2021;6(1):412.
PubMed PubMed Central Article Google Scholar
Gao R, Zhang Y, Zeng C, Li Y. The role of NFAT in the pathogenesis and targeted therapy of hematological malignancies. Eur J Pharmacol. 2022;921:174889.
CAS PubMed Article Google Scholar
Chandran SS, Klebanoff CA. T cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance. Immunol Rev. 2019;290(1):127–47.
CAS PubMed PubMed Central Article Google Scholar
Chen L, Qiao DJ, Wang JT, Tian G, Wang MJ. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers. Immunol Lett. 2019;216:51–62.
CAS PubMed Article Google Scholar
Biernacki MA, Brault M, Bleakley M. T-cell receptor-based immunotherapy for hematologic malignancies. Cancer J. 2019;25(3):179–90.
CAS PubMed PubMed Central Article Google Scholar
Lin C, Li Y. The role of peptide and DNA vaccines in myeloid leukemia immunotherapy. Cancer Cell Int. 2013;13(1):13.
CAS PubMed PubMed Central Article Google Scholar
Li Y, Lin C, Schmidt CA. New insights into antigen specific immunotherapy for chronic myeloid leukemia. Cancer Cell Int. 2012;12(1):52.
PubMed PubMed Central Article CAS Google Scholar
Dembic Z, Haas W, Weiss S, McCubrey J, Kiefer H, von Boehmer H, et al. Transfer of specificity by murine alpha and beta T-cell receptor genes. Nature. 1986;320(6059):232–8.
CAS PubMed Article Google Scholar
Zhang Y, Xu L, Chen S, Zha X, Wei W, Li Y. Identification of TCR Vbeta11-2-Dbeta1-Jbeta1-1 T cell clone specific for WT1 peptides using high-throughput TCRbeta gene sequencing. Biomark Res. 2019;7:12.
PubMed PubMed Central Article Google Scholar
Chen C, Liu SM, Chen Y, Ou Q, Bao H, Xu L, et al. Predictive value of TCR Vbeta-Jbeta profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial. JCI Insight. 2022;7(1):e152631.
PubMed PubMed Central Article Google Scholar
Wang X, Chen Y, Li Z, Huang B, Xu L, Lai J, et al. Single-Cell RNA-Seq of T Cells in B-ALL patients reveals an exhausted subset with remarkable heterogeneity. Adv Sci (Weinh). 2021;8(19):e2101447.
Kisielow J, Obermair F-J, Kopf M. Deciphering CD4 T cell specificity using novel MHC-TCR chimeric receptors. Nat Immunol. 2019;20(5):652–62.
CAS PubMed Article Google Scholar
Cole DJ, Weil DP, Shamamian P, Rivoltini L, Kawakami Y, Topalian S, et al. Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope. Cancer Res. 1994;54(20):5265–8.
Sensi M, Traversari C, Radrizzani M, Salvi S, Maccalli C, Mortarini R, et al. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. Proc Natl Acad Sci U S A. 1995;92(12):5674–8.
CAS PubMed PubMed Central Article Google Scholar
Farina C, van der Bruggen P, Boel P, Parmiani G, Sensi M. Conserved TCR usage by HLA-Cw* 1601-restricted T cell clones recognizing melanoma antigens. Int Immunol. 1996;8(9):1463–6.
CAS PubMed Article Google Scholar
Lake DF, Salgaller ML, van der Bruggen P, Bernstein RM, Marchalonis JJ. Construction and binding analysis of recombinant single-chain TCR derived from tumor-infiltrating lymphocytes and a cytotoxic T lymphocyte clone directed against MAGE-1. Int Immunol. 1999;11(5):745–51.
CAS PubMed Article Google Scholar
Jager E, Maeurer M, Hohn H, Karbach J, Jager D, Zidianakis Z, et al. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. Int J Cancer. 2000;86(4):538–47.
CAS PubMed Article Google Scholar
Fujio K, Misaki Y, Setoguchi K, Morita S, Kawahata K, Kato I, et al. Functional reconstitution of class II MHC-restricted T cell immunity mediated by retroviral transfer of the alpha beta TCR complex. J Immunol. 2000;165(1):528–32.
CAS PubMed Article Google Scholar
Zha X, Xu L, Chen S, Yang L, Zhang Y, Lu Y, et al. Generation of V alpha13/beta21 + T cell specific target CML cells by TCR gene transfer. Oncotarget. 2016;7(51):84246–57.
PubMed PubMed Central Article Google Scholar
El Hage F, Vergnon I, Grunenwald D, Soria JC, Chouaib S, Mami-Chouaib F. Generation of diverse mutated tumor antigen-specific cytotoxic T lymphocytes in a lung cancer patient with long survival. Oncol Rep. 2005;14(3):763–9.
留言 (0)